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Abstract
Introduction The prognostic significance of HER-2/neu  in
breast cancer is a matter of controversy. We have performed a
study in 101 node-negative breast cancer patients with long-
term follow-up not treated in the adjuvant setting, and analysed
the prognostic significance of immunohistochemistry (IHC) and
fluorescence in situ hybridisation (FISH), both separately and in
combination, in comparison with traditional prognostic factors.
Methods Overexpression was classified semiquantitatively
according to a score (0 to 3+) (HER-2_SCO). FISH was used
to analyse HER2/neu  amplification (HER-2_AMP). Patients
classified 2+ by IHC were examined with FISH for amplification
(HER-2_ALG). Patients with 3+ overexpression as well as
amplification of HER-2/neu  were positive for the combined
variable HER2_COM. These variables were compared with
tumour size, histological grade and hormone receptor status.
Results HER-2_SCO was 3+ in 20% of all tumours. HER-
2_ALG was positive in 22% and amplification (HER-2_AMP)
was found in 17% of all tumours. Eleven percent of the tumours
showed simultaneous 3+ overexpression and amplification.
Only histological grade (relative risk [RR] 3.22, 95% confidence
interval [CI] 1.73–5.99, P  = 0.0002) and HER-2_AMP (RR
2.47, 95% CI 1.12–5.48, P  = 0.026) were significant for
disease-free survival in multivariate analysis. For overall survival,
both histological grade (RR 3.89, 95% CI 1.77–8.55, P  =
0.0007) and HER-2_AMP (RR 3.08, 95% CI 1.24–7.66, P =
0.016) retained their independent significance.
Conclusion The prognostic significance of HER-2/neu in node-
negative breast cancer depends on the method of testing: only
the amplification of HER-2/neu is an independent prognostic
factor for the long-term prognosis of untreated node-negative
breast cancer.
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Introduction
Human epidermal growth factor receptor-2 is a proto-onco-
gene that encodes a cell-surface receptor designated
HER-2/neu or c-erbB-2. Gene amplification and/or protein
overexpression occurs in 14–30% of all breast cancers [1-
3]. Initially, the adverse prognostic impact of HER-2/neu in
breast cancer was the main focus of research. However,
results from different study groups were not entirely con-
sistent. Studies that supported the initially reported
adverse prognosis in breast cancer [1,3] were later fol-
lowed by reports that failed to show any association with
prognosis [4,5]. Although no consensus exists concerning
the prognostic value of HER-2/neu, an increasing quantity
of data indicates a predictive value for the efficacy of cer-
tain adjuvant therapies. The response of HER-2/neu-posi-
tive breast cancer patients to tamoxifen is significantly
worse than for HER-2/neu-negative patients [6,7] even
though this point of view is not unopposed [8,9]. More
recently, it was shown that aromatase inhibitors might pro-
vide more benefit than tamoxifen in patients with tumours
positive for erbB-1 and/or erbB-2 [10].
However, the strongest evidence for a predictive role for
HER-2/neu  comes from several retrospective trials that
consistently showed that HER-2/neu-positive patients
responded better to an anthracycline-based therapy than to
treatment with cyclophosphamide, methotrexate and fluor-
ouracil [11-13]. Because of this predictive impact of HER-
CI = confidence interval; DFS = disease-free survival; FISH = fluorescence in situ hybridisation; IHC = immunohistochemistry; OS = overall survival; 
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2/neu, many of the studies on the prognostic role of HER-
2/neu  cannot be reliably interpreted when the patients
enrolled were treated in an adjuvant setting. To avoid this
potential bias, we have performed a retrospective study on
the prognostic impact of HER-2/neu in a historical cohort
of node-negative T1/T2 breast cancer patients who were at
that time not being treated in an adjuvant setting.
A point of utmost importance when assessing the utility of
HER-2/neu as a prognostic factor is the technique of HER-
2/neu  testing. Principally, gene-based assays such as
Southern blot analysis or fluorecence in situ hybridisation
(FISH) have to be distinguished from assays that assess
the level of protein expression, such as western blot analy-
sis or immunohistochemistry (IHC). When analysing the
published studies of HER-2/neu as a prognostic factor with
regard to the technique used, Ross and colleagues [14,15]
found that those studies that applied FISH to the assess-
ment of gene amplification found an association of HER-2/
neu with the prognosis of the patients, whereas studies
that used IHC for the assessment of protein expression
gave rather ambiguous results. Reasons for the apparently
worse performance of IHC than that of FISH could be dif-
ferences in the sensitivity of the applied antibodies [16] or
the lack of a uniform scoring system in most of the older
studies that used IHC. Standardisation of HER-2/neu test-
ing has received considerably more attention in recent
years owing to the advent of trastuzumab, a monoclonal
antibody that affords prolonged survival in patients with
metastatic breast cancer [17]. To improve the quality of
IHC when testing for HER-2/neu status before starting a
therapy with trastuzumab, a standardised scoring protocol
was developed. On the basis of these findings, an algo-
rithm incorporating FISH only in doubtful cases (2+ in IHC)
was introduced.
The aim of our present study on 101 node-negative breast
cancer cases was to compare gene amplification by FISH
with protein expression by IHC with the standardised scor-
ing system, the above-mentioned algorithm and the combi-
nation of HER-2/neu overexpression and amplification in
the prognostic value of HER-2/neu.
Methods
Patients
The study cohort consisted of 101 lymph-node-negative
breast cancer patients who were treated at the Department
of Obstetrics and Gynecology of the Johannes Gutenberg
University Mainz between 1988 and 1993. Patients were
all treated with surgery and did not receive any systemic
therapy in the adjuvant setting. The established prognostic
factors (tumour size, histological grade and steroid recep-
tor status) were collected from the original pathology
reports of the gynaecological pathology division within our
department.
Patients were treated either with modified radical mastec-
tomy (n = 58) or breast-conserving surgery followed by irra-
diation (n = 43). Because the administration of adjuvant
systemic therapy was not allowed in this study, we focused
on node-negative breast cancer patients with pT1 and pT2
tumours and without any evidence of metastasis at the time
of surgery. The median age of the patients at surgery was
56 years (range 29–86 years).
The median time of follow-up was 131 months for the
patients still alive at the time of analysis. Within this follow-
up period, 31 patients relapsed, 20 patients died of breast
cancer and 10 patients died of unrelated causes. The
patients dying of causes other than breast cancer were
censored for the survival analyses at their date of death.
HER-2/neu amplification determined by FISH
FISH for HER-2/neu  gene amplification was performed
with the Appligene Oncor HER-2/neu gene amplification
system (Ventana Medical Systems, Tucson, AZ, USA), fol-
lowing the supplier's instructions. In brief, fresh frozen
slides were first treated with a protein-digesting enzyme at
37°C for 10 min, washed in 2× sodium chloride/sodium cit-
rate (SSC) at 22°C, dehydrated in an 75–100% ethanol
series and air dried. Tissue sections were than denatured
for 5 min in 70% formamide, pH 7.5, at 75°C, followed by
rinsing with 100% ethanol and air drying. Appligene Oncor
HER-2/neu DNA probe was prewarmed for 5 min at 37°C
before application. Slides were than incubated for 24 hours
at 37°C in a humidified chamber. After hybridisation, the
slides were washed in 2× SSC for 5 min at 72°C; this was
then followed by a wash in phosphate-buffered detergent
(Oncor, Gaithersburg, MD, USA) at room temperature for 5
min. Detection was achieved with the Appligene Oncor flu-
orescein-labelled anti-digoxigenin antibody (Ventana Medi-
cal Systems). The slides were incubated with this antibody
for 5 min in a humidified chamber at 37°C. Slides were then
subjected to three washes (2 min each) in phosphate-buff-
ered detergent at room temperature and were stored in the
dark at -20°C for up to 5 days before analysis. The nuclei
were counterstained with a propidium iodide/antifade solu-
tion (Oncor, Gaithersburg, MD, USA). Appropriate positive
controls were included in each staining run. A serial section
of each slide used for FISH was stained with haematoxylin
and eosin to control for the presence of invasive tumour
formations.
Additionally, serial sections (6 µm thick) of formalin-fixed
paraffin-embedded blocks from five randomly selected
amplified and five randomly selected non-amplified tumours
were deparaffinised and then subjected to the staining pro-
tocol outlined above.Available online http://breast-cancer-research.com/content/7/2/R256
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Interpretation of FISH results
Analysis was performed with an Axioskop fluorescence
microscope (Zeiss, Jena, Germany). Images were captured
with an analogue camera (Leica, Bensheim, Germany). In
each quadrant of the slide, the number of fluorescein sig-
nals was counted in 20 nuclei of invasive tumour cells (that
is, a total of 80 tumour nuclei). Cases were considered
amplified if the mean number of fluorescence signals was
greater than four (HER2_AMP) [18]. Additionally, we com-
pared tumours with low-level amplification (five or six sig-
nals per nucleus) against tumours with a higher level of
amplification (more than six signals per nucleus).
HER-2/neu expression determined by IHC
The immunohistochemical staining with a monoclonal anti-
body against HER-2/neu was performed as described pre-
viously [19]. In brief, serial sections (4 µm thick) of formalin-
fixed, paraffin-embedded blocks were first deparaffinised.
They were then microwaved in 10 mM citrate buffer, pH
6.0, to unmask epitopes and treated for 10 min with 1%
hydrogen peroxide to block endogenous peroxidase. The
sections were incubated for 30 min at 37°C with mono-
clonal HER-2/neu antibodies (clone CB-11; Novocastra,
Newcastle upon Tyne, UK) diluted 1:50. The sections were
then incubated with a biotin-labelled secondary antibody
and streptavidin–peroxidase for 20 min each. Tissue was
subsequently treated for 5 min with 0.05% 3',3-diami-
nobenzidine tetrahydrochloride and lightly counterstained
with haematoxylin. All series included appropriate positive
and negative controls. All controls gave adequate results.
Interpretation of IHC results
Only cases showing unequivocal staining of membranes
were regarded as positive for HER-2/neu overexpression
[2]. A score was determined in accordance with the criteria
used in the approval trials for trastuzumab [17,20]. In brief,
cases showing no staining were scored 0, cases with less
than 10% membrane staining 1+, cases with more than
10% weak to moderate complete membrane staining 2+,
and cases with more than 10% strong complete membrane
staining 3+ (HER2_SCO). Only 3+ cases were considered
positive for survival analyses.
Interpretation of combined IHC and FISH results
Cases that were scored 2+ by IHC were considered posi-
tive for the HER-2/neu algorithm [21] only if they showed
an amplification of HER-2/neu (HER2_ALG).
Finally, cases showing HER-2/neu amplification as well as
overexpression with an immunohistochemical score of 3+
were considered positive for the combined HER-2/neu
evaluation (HER2_COM).
Statistical analysis
The concordance between two methods was assessed by
using the kappa test. The sensitivity and specificity of IHC
(HER2_SCO) were evaluated, with the use of FISH as ref-
erence method. Life tables were calculated in accordance
with the Kaplan–Meier method. Disease-free survival (DFS)
was computed from the date of diagnosis to the date of
recurrence of disease. Overall survival (OS) was computed
from the date of diagnosis to the date of death from breast
cancer. Patients who died of an unrelated cause were cen-
sored at the date of death. Survival curves were compared
with the log-rank test. Univariate Cox survival analyses were
performed and multivariate analyses were done in a back-
ward stepwise fashion with the Cox proportional hazards
model. All tests were performed at a significance level of α
= 0.05. All P values are two-sided.
Results
Distribution of traditional and HER-2/neu-related 
factors
In a group of 101 node-negative patients with primary
breast cancer of sizes T1 and T2 without systemic treat-
ment in the adjuvant setting, established pathological and
clinical parameters (tumour size, histological grade, steroid
hormone receptor status, age and menopausal status) and
HER-2/neu-related parameters (HER2_AMP, HER2_SCO,
HER2_ALG and HER2_COM) were assessed and are pre-
sented in Table 1; 36% of the patients were premenopau-
sal and perimenopausal. Tumour size was T1 in 57% and
T2 in the remaining 43%. A total of 64% of the patients had
tumours with a positive steroid hormone receptor status;
that is, they were oestrogen receptor and/or progesterone
receptor positive. A favourable histological grade (G I) was
present in 17%, G II in 58% and G III in 20%. Five percent
had medullary carcinomas and were therefore not assigned
a histological grade.
HER-2/neu overexpression classified as 3+ as assessed
by IHC was found in 20% (HER2_SCO); 17% of tumours
showed an amplification of HER-2/neu  by FISH
(HER2_AMP). Of the amplified cases, five tumours showed
five or six signals per nucleus, indicating low-level amplifi-
cation, and 12 tumours showed more than six signals per
nucleus (evidence of a higher level of amplification). Two of
the patients who were scored as 2+ by IHC also exhibited
an amplification of HER-2/neu. This resulted in a total of
22% of the patients being positive for HER2_ALG. Finally,
in 11% of the patients an amplification as well as a 3+ over-
expression of HER-2/neu was found (HER2_COM).
The estimated DFS was 70% and the breast cancer-spe-
cific OS was 80% at 10 years for the whole group of
patients.Breast Cancer Research    Vol 7 No 2    Schmidt et al.
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Concordance of amplification status in formalin-fixed 
paraffin-embedded tumour samples with fresh-frozen 
tumour samples
All five tumours amplified for HER-2/neu in frozen tumour
samples were also amplified when formalin-fixed paraffin-
embedded tumour samples were used. Similarly, complete
concordance was found between frozen and formalin-fixed
tissue samples when five tumours without amplification
were compared pair by pair.
Concordance of HER2_AMP and HER2_SCO
A concordance between amplification and HER2_SCO
was detected in 86 cases (85%) when only 3+ cases were
considered positive for HER2_SCO. Six cases with
Table 1
Clinicopathological characteristics of 101 patients with node-negative primary breast cancer
Characteristic n %
Age at diagnosis
Less than 50 36 36
More than 50 65 64
Menopausal status
Pre/perimenopausal 36 36
Postmenopausal 65 64
pT stage
pT1a,b 16 16
pT1c 42 42
pT2 43 43
Histological grade
GI 17 17
GII 59 58
GIII 20 20
Not done (medullary carcinomas) 5 5
Steroid hormone receptor status
Positive 65 64
Negative 36 36
HER2_SCO
0, 1+ 63 62
2+ 18 18
3+ 20 20
HER2_AMP
Positive 17 17
Negative 84 83
HER2_ALG
Positive 22 22
Negative 79 78
HER2_COM
Positive 11 11
Negative 90 89Available online http://breast-cancer-research.com/content/7/2/R256
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amplification did not score 3+, whereas nine 3+ cases
failed to show an amplification. This resulted in a degree of
concordance (kappa) of 0.50 (95% CI 0.29–0.72).
Sensitivity and specificity of HER2_SCO
The sensitivity of HER2_SCO 3+ with FISH as reference
method was 65% (11 of 17 amplified cases) and specifi-
city was 89% (75 of 84). Considering also 2+ cases as
positive resulted in an increase in sensitivity to 76% (13 of
17 amplified cases) with a decreased specificity of 70%
(59 of 84).
Breast cancer-specific DFS
In univariate analysis (Table 2) neither age at diagnosis nor
menopausal status, tumour size or steroid hormone recep-
tor status had a significant influence on the DFS. From the
classical prognostic factors only histological grade turned
out to be significantly related to DFS (P = 0.0002; RR
3.26, 95% CI 1.77–5.99) for DFS. Among the HER-2/neu-
related variables, HER2_ALG did not show an influence on
DFS, whereas HER2_SCO had a borderline significance
(P = 0.059, RR 1.46, 95% CI 0.99–2.16). In contrast, both
HER2_AMP (P = 0.004, RR 3.07, 95% CI 1.44–6.57) and
HER2_COM (P = 0.006, RR 3.27, 95% CI 1.40–7.65)
had a significant influence on the DFS. There was no signif-
icant difference in DFS between tumours with low-level
amplification (five or six copies per nucleus) and tumours
with a higher level of amplification. Three of five and 7 of 12
patients relapsed, respectively. The Kaplan–Meier esti-
mates that yielded significant results are shown in Fig. 1.
We then conducted a multivariate Cox regression in a
backward fashion. In this Cox regression only histological
grade (P  = 0.0002, RR 3.22, 95% CI 1.73–5.99) and
HER2_AMP (P = 0.026, RR 2.47, 95% CI 1.12–5.48)
retained an independent prognostic significance (Table 3).
Breast cancer-specific OS
In univariate analysis (Table 4) neither age at diagnosis nor
menopausal status or tumour size had a significant influ-
ence on the OS. From the classical prognostic factors only
histological grade (P = 0.0003, RR 4.27, 95% CI 1.96–
9.29) and the steroid hormone receptor status (P = 0.012,
RR 0.32, 95% CI 0.13–9.78) were significant in univariate
analysis for OS. Among the HER-2/neu-related variables,
HER2_ALG did not show any influence on OS whatsoever.
However, HER2_SCO (P  = 0.047, RR 1.60, 95% CI
1.01–2.53) as well as HER2_AMP (P = 0.004, RR 3.78,
95% CI 1.54–9.26) and HER2_COM (P  = 0.004, RR
4.18, 95% CI 1.60–10.90) had a significant influence on
the OS. There was no significant difference in OS between
tumours with low-level amplification (five or six copies per
nucleus) and tumours with a higher level of amplification.
Three of five and 5 of 12 patients died of breast cancer,
respectively. The Kaplan–Meier estimates that yielded sig-
nificant results are shown in Fig. 2. In a multivariate Cox
regression analysis only histological grade (P = 0.0007,
RR 3.89, 95% CI 1.77–8.55) and HER2_AMP (P = 0.016,
RR 3.08, 95% CI 1.24–7.67) retained an independent
prognostic significance (Table 5).
Discussion
The prognostic value of HER-2/neu has always been con-
troversial. Studies showing a shorter DFS and/or OS for
HER-2/neu-positive patients [3,18,22,23] were opposed
by studies which failed to find such an association [4,5]. In
an earlier series from our department [24] an association
with survival was shown only for node-positive, but not for
node-negative, breast cancer patients. This association
with prognosis in node-positive patients, who are almost
uniformly treated with systemic therapy, might be markedly
influenced by the ability of HER-2/neu  status to affect
responsiveness to systemic treatment [11-13]. In any case,
the actual role of HER-2/neu as a predictive marker is still
Table 2
Univariate analysis for breast cancer-specific disease-free survival
Prognostic factor P RR 95% CI
Age n.s. - -
Menopausal status n.s. - -
pT stage n.s. - -
Grade 0.0002 3.35 1.77–5.99
Steroid hormone receptor status n.s. - -
HER2_SCO n.s.
HER2_AMP 0.004 3.07 1.44–6.57
HER2_ALG n.s. - -
HER2_COM 0.006 3.27 1.40–7.65
CI, confidence interval; n.s., not significant; RR, relative risk.Breast Cancer Research    Vol 7 No 2    Schmidt et al.
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Figure 1
Effect of histological grade, HER2_SCO, HER2_AMP and HER2_COM on disease-free survival Effect of histological grade, HER2_SCO, HER2_AMP and HER2_COM on disease-free survival. (a) Grade; (b) HER2_SCO; (c) HER2_AMP; (d) 
HER2_COM.
Table 3
Multivariate analysis for breast cancer-specific disease-free survival
Prognostic factor P RR 95% CI
Age n.s. - -
Menopausal status n.s. - -
pT stage n.s. - -
Grade 0.0002 3.22 1.73–5.99
Steroid hormone receptor status n.s. - -
HER2_SCO n.s. - -
HER2_AMP 0.026 2.47 1.12–5.48
HER2_ALG n.s. - -
HER2_COM n.s. - -
CI, confidence interval; n.s., not significant; RR, relative risk.Available online http://breast-cancer-research.com/content/7/2/R256
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a matter of debate [25]. In our present study, we could rule
out any such interference of purely prognostic with treat-
ment-related predictive effects because we examined only
node-negative patients without any systemic therapy in the
adjuvant setting.
When examining the techniques used for the assessment
of the HER-2/neu status, gene-based assays almost uni-
formly confirmed the negative prognostic impact of HER-2/
neu in node-negative patients. Especially in the past few
years, FISH has gained considerable interest as a reliable
and valid method for determining the HER-2/neu status,
confirming its prognostic utility [18,26]. Compared with
other gene-based assays such as Southern blotting or
polymerase chain reaction, FISH is not hampered by dilu-
tional artefacts possibly resulting from a mixture of different
cell populations. Similarly to IHC it allows for the specific
detection of the alteration in individual cells within the
important architectural context. However, in comparison
with IHC, FISH is rather time-consuming and leads to sub-
stantial costs [27]. It is nevertheless considered the gold
standard for assessing HER-2/neu status. A potential
advance in the practicability of in situ hybridisation could
be the more recently described chromogenic in situ hybrid-
isation, which has shown a good correlation with FISH [28]
and an independent prognostic importance in patients with
node-negative breast cancer [23].
When determining the amplification of HER-2/neu  with
FISH in our cohort of 101 untreated node-negative breast
cancer patients, we found 17% with an amplification of the
gene locus. This fraction is largely in line with the literature
[18,26,29-31]. The amplification of HER-2/neu measured
by FISH showed a significant correlation with the DFS and
OS. This strong association between amplification of HER-
2/neu and survival of lymph-node-negative breast cancer
patients is consistent with previous studies [18,23,26,30].
Only one group could document this association only for
OS but not for DFS [32]. Searching for an explanation for
their deviating results, the authors speculated that HER-2/
neu  might be more a predictive factor for treatment
response than a prognostic factor per se because all
patients in their study had been treated systemically after
relapse.
In contrast with HER-2/neu gene amplification, overexpres-
sion of HER-2/neu was not associated with survival in sev-
eral studies [4,5,33] even though others found a
prognostic impact [22,23,34]. More recently, Volpi and col-
leagues [35] found a prognostic significance of HER-2/neu
overexpression only for a subgroup of patients with high
proliferative activity, whereas they failed to show any prog-
nostic significance of HER-2/neu  overexpression in the
overall series of node-negative breast cancer patients.
These apparent discrepancies have largely prevented the
widespread acceptance of HER-2/neu as a prognostic fac-
tor in node-negative breast cancer up to now [36].
Several possible reasons could account for these contro-
versial findings. One frequently quoted, simple but none-
theless unsatisfactory reason could be the rather small
sample size of several studies. However, a strong and bio-
logically relevant prognostic factor should eventually
become evident even within a small sample size. Another
possible reason is the remarkable discrepancy in sensitivity
between the numerous antibodies used [16] and differ-
ences in tissue fixation and processing [37]. However, per-
h a p s  t h e  m o s t  i m p o r t a n t  r e a s o n  i s  t h e  l a c k  o f  a
standardised evaluation protocol in many of the older stud-
ies. The standardisation of IHC has become increasingly
important since the successful use of trastuzumab (Her-
ceptin™) in the treatment of HER-2/neu-overexpressing
metastatic breast cancer [17,20,38]. The United States
Food and Drug Administration has approved a standard-
Table 4
Univariate analysis for breast cancer-specific overall survival
Prognostic factor P RR 95% CI
Age n.s. - -
Menopausal status n.s. - -
pT stage n.s. - -
Grade 0.0003 4.26 1.96–9.29
Steroid hormone receptor status 0.012 0.32 0.13–0.78
HER2_SCO 0.047 1.60 1.01–2.53
HER2_AMP 0.004 3.78 1.54–9.26
HER2_ALG n.s. - -
HER2_COM 0.004 4.18 1.60–10.90
CI, confidence interval; n.s., not significant; RR, relative risk.Breast Cancer Research    Vol 7 No 2    Schmidt et al.
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ised IHC kit (HercepTest™; Dako) with a detailed published
scoring system ranging from 0 to 3+. However, the Her-
cepTest has a rather low specificity, as outlined by Jacobs
and colleagues [39]. The studies mentioned above that led
to the approval of trastuzumab for HER-2/neu-positive
metastatic breast cancer used a cocktail of different anti-
bodies, one of which, the monoclonal antibody CB11, was
used in our study.
Figure 2
Effect of histological grade, steroid hormone receptor status, HER2_SCO, HER2_AMP and HER2_COM on overall survival Effect of histological grade, steroid hormone receptor status, HER2_SCO, HER2_AMP and HER2_COM on overall survival. (a) Grade; (b) steroid 
hormone receptor status; (c) HER2_SCO; (d) HER2_AMP; (e) HER2_COM.Available online http://breast-cancer-research.com/content/7/2/R256
R264
When we adapted the scoring system defined for the Her-
cepTest to the CB11 antibody we used in our study, we
found a borderline significant correlation with survival.
To our opinion, the concordance between FISH and IHC
was only moderate at best with a rate of 85%, even though
we regarded only 3+ cases as overexpressing HER-2/neu.
This level of concordance is in line with previously pub-
lished results [40]. However, others found higher levels of
concordance between FISH and IHC, ranging from 92%
up to 98% [39,41,42].
When FISH results were compared with IHC data by using
computer-assisted image analysis, we showed previously
that concordance rates can be significantly improved when
the IHC signal is corrected by the subtraction of non-spe-
cific cytoplasmic chromogen deposition [43], suggesting
that only the strictly membrane-confined IHC signal can be
considered truly positive when estimating HER-2/neu IHC
slides. However, similarly to our findings others have failed
to detect oncogene amplification by FISH in as many as
51% of tumours with strong 3+ staining [44]. Because
overexpression of HER-2/neu  is not necessarily caused
only by amplification, polysomy of chromosome 17 has to
be taken into account [45]. This polysomy of chromosome
17 could well lead to an incorrect diagnosis of a low-level
amplification using single-colored FISH. However, in our
study tumours with five or six copies of HER-2/neu had a
survival comparable to that of tumours with a higher level of
amplification. As a consequence of the moderate concord-
ance, sensitivity and specificity for IHC in our study were
lower than described by others [41,42]. However, our find-
ings with the frequently used antibody CB11 should not be
generalised to IHC as a whole because different antibodies
show well-documented differences in terms of sensitivity
and specificity [16].
Cases reported as 2+ by IHC should be reassessed with
FISH in accordance with the test algorithm used in meta-
static breast cancer before the start of a therapy with tras-
tuzumab [21]. To the best of our knowledge we are the first
group to use this algorithm to assess the prognosis in
node-negative breast cancer patients. The use of this algo-
rithm found 2 of 18 2+ tumours amplified and hence
increased the percentage of tumours positive for HER-2/
neu to 22%. A similar percentage of HER-2/neu-positive
cases has previously been reported when performing FISH
only in uncertain cases after IHC with the HercepTest [46].
For these authors, decreases in time and costs were
quoted as strong arguments in favour of using this same
testing algorithm for the determination of HER-2/neu sta-
tus.
Because overexpression of HER-2/neu does not necessar-
ily mirror amplification and vice versa, and because both
parameters have been correlated with a poor outcome, we
investigated whether the combination of amplification and
overexpression could be useful in identifying a subgroup of
patients with a particularly dismal prognosis. Altogether, 11
tumours showed amplification and overexpression (defined
by a score of 3+). Indeed, these patients had a significantly
worse prognosis than the remainder of the study cohort.
These results are comparable to the data of Sauer and col-
leagues [31], who also found a markedly adverse prognos-
tic effect in this dual-positive subgroup. Nonetheless, in our
multivariate analysis, the combination of both techniques
did not add additional prognostic information to that
obtained by the amplification alone. However, owing to the
relatively small number of events, especially for
HER2_COM, subtle differences might be difficult to
address adequately.
To assess the clinical relevance of these findings, we
included the HER-2/neu-dependent variables
Table 5
Multivariate analysis for breast cancer-specific overall survival
Prognostic factor P RR 95% CI
Age n.s. - -
Menopausal status n.s. - -
pT stage n.s. - -
Grade 0.0007 3.89 1.77–8.55
Steroid hormone receptor status n.s. - -
HER2_SCO n.s. - -
HER2_AMP 0.016 3.08 1.24–7.66
HER2_ALG n.s. - -
HER2_COM n.s. - -
CI, confidence interval; n.s., not significant; RR, relative risk.Breast Cancer Research    Vol 7 No 2    Schmidt et al.
R265
(HER2_SCO, HER2_AMP, HER2_ALG and HER2_COM)
into a multivariate model with the variables tumour size, his-
tological grade and steroid receptor status. These last
three variables are commonly accepted for risk assessment
in node-negative breast cancer [36]. The factor age (not
more than 35 years at diagnosis) was ignored because only
one patient in our cohort was younger than 35. In this mul-
tivariate analysis, only histological grade and HER-2/neu
amplification were identified as independent prognostic
factors for DFS and OS, respectively.
We therefore conclude that HER-2/neu is an independent
prognostic factor in node-negative breast cancer, even
though its prognostic utility is largely influenced by the
method of testing.
To further validate these observations, a prospective study
in patients not treated in an adjuvant setting would be desir-
able. However, this is largely precluded in practice, given
the recent consensus recommendations for the treatment
of primary breast cancer [36]. For this reason we are cur-
rently engaged in a formal meta-analysis of all published
studies that have used FISH or chromogenic in situ hybrid-
isation to determine the HER-2/neu status and hope to
clarify once and for all the controversial status of HER-2/
neu as a prognostic factor in breast cancer.
Conclusions
The prognostic significance of HER-2/neu in node-nega-
tive breast cancer depends strongly on the method of test-
ing: only the amplification of HER-2/neu is an independent
prognostic factor for the long-term prognosis of untreated
node-negative breast cancer.
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